Blueprint's longtime CEO prepares to step down as biotech revels in new Ayvakit launch, pipeline expansion
After a busy 2021 brought Blueprint Medicines its fourth FDA approval, the company is kicking off the new year with plans to shake up its C-suite.
Jeff Albers, Blueprint’s CEO for the past eight years, will be stepping down April 4 and transitioning to the executive chairman position, the biotech announced Wednesday morning. He will be replaced by COO Kate Haviland, who moves into both the chief executive and president roles. Christina Rossi also nabs a promotion from chief commercial officer to COO.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,700+ biopharma pros reading Endpoints daily — and it's free.